Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
International + Font Resize -

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials

Helsinki
Tuesday, February 4, 2025, 16:00 Hrs  [IST]

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, announced it has closed a EUR 7 million financing. The funding round was led by new investors Fåhraeus Startup and Growth AB (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund. FSG and EIC Fund were joined by leading Finnish investors, including Jenny and Antti Wihuri Foundation, Innovestor and Gösta Serlachius Fine Arts Foundation.

By mimicking naturally occurring mast cell-derived heparin proteoglycans, APAC targets arterial injury sites providing long-lasting antithrombotic and anti-inflammatory action in situ. The funding will support the initiation of phase 2a clinical trial of APAC for peripheral arterial occlusive disease/chronic limb threatening ischemia (PAOD/CLTI) in Finland. APAC is also poised to complete three ongoing clinical trials; a phase I clinical trial for Arteriovenous Fistula (AVF) maturation failure, a Phase I intravenous (IV) clinical trial in healthy participants, and a PET-imaging clinical trial with 89 zirconium-labelled APAC in PAOD patients and healthy participants in 2025.

APAC is intended for in-hospital use and can be administered either locally or by IV infusion. Over 40 participants have so far received APAC without any safety concerns and initial clinical findings are encouraging.

Aki Prihti, CEO at Aplagon, said, ‘We’re delighted to secure this fund-raising, and to bring on board FSG and EIC Fund as highly experienced VC investors from outside Finland. We have been making strong progress, and this financing enables us to complete the three international clinical trials we have been running with APAC, and to start a phase 2a study in PAOD/CLTI. Our innovative approach, using a heparin proteoglycan mimetic with targeting ability and retention on the vascular injury sites, has potential applications across a broad range of serious vascular diseases. We are looking forward to announcing clinical results from these trials in 2025 and 2026.”

Johanna Asklin, general partner at FSG, said, “Thrombo-inflammation is a key underlying driver for many cardiovascular diseases. At FSG we look for revolutionary innovations, and we found precisely that with Aplagon’s APAC approach to treat this clear unmet medical need.”

Johanna Asklin will join Aplagon as a Board member and Alexander Jöndell, Partner at FSG, as an Observer.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
Asia_Lab_Expo2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram